Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Beacon Topco Q3 2026 Results: Net Loss of $6.1M, Loss Narrows

For the nine months ended September 30, 2026, Beacon Topco reported a net loss of $22.2 million, a significant reduction from the $55.4 million loss in the prior year period. The company maintained a cash position of $49.2 million and plans to rename itself Clywedog Therapeutics Holdings, Inc. following a pending merger transaction.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-6.1-14.6
Net income-6.1-14.6
EPS (diluted, $ a share)$-1.34$-3.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Beacon Topco, Inc.: key numbers

Shares outstanding
100Latest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Beacon Topco, Inc.

All →
4:19 PM ET 8-K
M&A Deal

Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.

Beacon Topco, Inc. entered into a third amendment to its merger agreement with Clywedog Therapeutics, Inc. and Barinthus Biotherapeutics plc. The amendment updates the expected closing timeline and extends the 'End Date' for the merger to November 13, 2026.

Counterparty
Clywedog Therapeutics, Inc.
9:19 AM ET 8-K
M&A Deal

Beacon Topco M&A Deal with Clywedog Therapeutics, Inc.

Beacon Topco, Inc. entered into a second amendment to its merger agreement with Clywedog Therapeutics, Inc., extending the expected closing date and the 'End Date' to October 31, 2026. The filing also disclosed positive Phase 1b clinical trial results for Clywedog's type 2 diabetes candidate, balomenib, which showed sustained glycemic improvement three months after treatment ended.

Counterparty
Clywedog Therapeutics, Inc.
6:01 AM ET 8-K
Stock Buyback

Beacon Topco Announces $15M Stock Buyback

Beacon Topco, Inc. launched a cash tender offer to repurchase up to $15 million of its common stock at a price of $6.6609 per share. The offer follows the completion of a transaction where the company acquired Barinthus Biotherapeutics plc via a court-sanctioned scheme of arrangement.

Value
$15M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.